Clinical Trial

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2029-05 -> 2029-08 2026-07-09
minor Completion pushed: 2030-05 -> 2030-08 2026-07-09
Trial Details
NCT Number NCT07521046
Lead Sponsor University of Utah
Collaborators: PharmaEssentia
Conditions Myelofibrosis
Enrollment 15 participants
Start Date 2026-08
Primary Completion 2029-08 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-08